Dasatinib in Treating Patients with Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Solar Melanoma that Cannot Be Removed by Surgery
The aim of this clinical trial is to study how well dasatinib works in treating patients with locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery.
Study Type: Interventional
Age/Sex Requirement: 18 years+ (None)
Sponsor: Eastern Cooperative Oncology Group
ClinicalTrials.gov Identifier: NCT00700882
Purpose: To study how well dasatinib works in treating patients with locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery. The primary outcome measure is objective tumor response rate. Secondary outcomes measures include response duration, progression-free survival, and safety profile.
Recent Videos
Related Content
